Diaceutics PLC Capital Markets Day and KPI Update (0174C)
16 Junio 2021 - 1:00AM
UK Regulatory
TIDMDXRX
RNS Number : 0174C
Diaceutics PLC
16 June 2021
16 June 2021
Diaceutics PLC
("Diaceutics" or "the Company")
Capital Markets Day and KPI Update
Diaceutics PLC , ( AIM: DXRX), the diagnostic commercialisation
company for precision testing will today host a virtual Capital
Markets Day ("CMD") for investors and equity analysts, from 1pm
BST.
The event will be led by Group CEO, Peter Keeling, and members
of the senior management team and will include a series of
presentations, a demonstration of the DXRX SaaS platform, views
from an industry expert panel including:
-- Pharmaceutical Partner: a senior executive within one of the
world's top five pharmaceutical companies
-- Laboratory Partner: Professor Giancarlo Pruneri, Head of
Pathology Fondazione IRCCS Istituto Nazionale Tumori, Milan
-- Key Opinion Leader: Dr Avi Kulkarni, SVP and R&D leader
at Nasdaq listed technology firm Cognizant.
In addition, there will be a strategic update from the Company,
along with a live Q&A.
A video replay of the presentation will be available via the
Group's website post-event.
To register for the DXRX Capital Markets Day or for any further
assistance or questions relating to the event, please contact
diaceutics@almapr.co.uk
Key Performance Indicator Updates
During the presentation, as part of the strategic update,
management will outline an update to a number of the Company's KPIs
(*) demonstrating continued positive progress with the uptake of
the DXRX platform and its impact on the Company's financial model
:
-- Over 40% of sales pipeline generation for Q2 is currently
represented by DXRX-enabled products on a contract value
basis(*)
-- 16% increase in average sales prices per project for Pharma
clients in 2021, when compared to the 2020 average contracted
price(*)
-- 10% increase in Gross Margin % (excluding amortisation and travel)(**)
-- 14 client projects live on DXRX platform as at end April
-- Six Diagnostic Partners and 10 Pharma partners recruited onto
the DXRX platform as at end April; and
-- 223 Lab partners recruited onto the DXRX platform as at end
April (growing substantially from the position of 101 partners as
at end March)
*Key Performance Indicator metrics as of 24 May 2021
**Key performance Indicator metrics as of 30 April 2021
Peter Keeling, CEO and Founder of Diaceutics PLC, commented: "We
continue to make excellent progress in the roll out of the DXRX
platform, our innovative diagnostic commercialisation platform for
precision medicine. We are seeing clear evidence of its value to
stakeholders within the Pharma industry and to Diaceutics,
providing us with the ability to scale our offering in line with
the increased growth in the precision medicine industry. In just a
few months post launch, we have built the foundations for platform
adoption at scale, achieving key expansion milestones such as lab
onboarding and are confident that we are on the path towards
becoming a strategically embedded platform provider to the Pharma
industry."
Enquiries:
Diaceutics PLC
Philip White, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDGPURCQUPGPUA
(END) Dow Jones Newswires
June 16, 2021 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024